Antenatal oral glucose tolerance test abnormalities in the prediction of future risk of postpartum diabetes in women with gestational diabetes: Results from the LIVING study
Authors:
- Yashdeep GuptaYGYashdeep Gupta
- Deksha KapoorDKDeksha Kapoor
- Josyula K. LakshmiJLJosyula K. Lakshmi
- Devarsetty PraveenDPDevarsetty Praveen
- Joseph Alvin SantosJSJoseph Alvin Santos
- Laurent BillotLBLaurent Billot
- Aliya NaheedANAliya Naheed
- Noshin FarzanaNFNoshin Farzana
- Renu JohnRJRenu John
- Saumiyah AjanthanSASaumiyah Ajanthan
Open Access
- 6 May 2024
- journal article
- research article
- Published by Wiley in Journal of Diabetes
- Vol. 16 (5) , e13559
Abstract
Objectives: To explore associations between type and number of abnormal glucose values on antenatal oral glucose tolerance test (OGTT) with postpartum diabetes in South Asian women diagnosed with gestational diabetes (GDM) using International Association of the Diabetes and Pregnancy Study Groups criteria.Methods: This post‐hoc evaluation of the Lifestyle Intervention IN Gestational Diabetes (LIVING) study, a randomized controlled trial, was conducted among women with GDM in the index pregnancy, across 19 centers in Bangladesh, India, and Sri Lanka. Postpartum diabetes (outcome) was defined on OGTT, using American Diabetes Association (ADA) criteria.Results: We report data on 1468 women with GDM, aged 30.9 (5.0) years, and with median (interquartile range) follow‐up period of 1.8 (1.4–2.4) years after childbirth following the index pregnancy. We found diabetes in 213 (14.5%) women with an incidence of 8.7 (7.6–10.0)/100 women‐years. The lowest incidence rate was 3.8/100 women years, in those with an isolated fasting plasma glucose (FPG) abnormality, and highest was 19.0/100 women years in participants with three abnormal values. The adjusted hazard ratios for two and three abnormal values compared to one abnormal value were 1.73 (95% confidence interval [CI], 1.18–2.54; p = .005) and 3.56 (95% CI, 2.46–5.16; p < .001) respectively. The adjusted hazard ratio for the combined (combination of fasting and postglucose load) abnormalities was 2.61 (95% CI, 1.70–4.00; p < .001), compared to isolated abnormal FPG.Conclusions: Risk of diabetes varied significantly depending upon the type and number of abnormal values on antenatal OGTT. These data may inform future precision medicine approaches such as risk prediction models in identifying women at higher risk and may guide future targeted interventions. imageKeywords
This publication has 20 references indexed in Scilit:
- Oral Glucose Tolerance Test Results in Pregnancy Can Be Used to Individualize the Risk of Future Maternal Type 2 Diabetes Mellitus in Women With Gestational Diabetes MellitusDiabetes Care, 2021
- Characteristics of gestational diabetes subtypes classified by oral glucose tolerance test valuesEuropean Journal of Clinical Investigation, 2021
- Association between the antepartum oral glucose tolerance test and the risk of future diabetes mellitus among women with gestational diabetes: A systematic review and meta-analysisJournal of Diabetes and its Complications, 2021
- Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetologia, 2020
- Cardiometabolic Risk Factors in Pregnancy and Implications for Long-Term Health: Identifying the Research Priorities for Low-Resource SettingsFrontiers in Cardiovascular Medicine, 2020
- Long term (>1 year) postpartum glucose tolerance status among Indian women with history of Gestational Diabetes Mellitus (GDM) diagnosed by IADPSG criteriaDiabetes Research and Clinical Practice, 2018
- Postpartum glucose intolerance: an updated overviewEndocrine, 2017
- Conversion of gestational diabetes mellitus to future Type 2 diabetes mellitus and the predictive value of HbA1c in an Indian cohortDiabetic Medicine, 2016
- International Association of Diabetes and Pregnancy Study Groups Recommendations on the Diagnosis and Classification of Hyperglycemia in PregnancyDiabetes Care, 2010
- A note on quantifying follow-up in studies of failure timeControlled Clinical Trials, 1996